Literature DB >> 33547230

Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years.

Sofia Ajeganova1,2, Ingiäld Hafström3,4, Johan Frostegård5.   

Abstract

OBJECTIVE: SLE is a strong risk factor for premature cardiovascular (CV) disease and mortality. We investigated which factors could explain poor prognosis in SLE compared with controls.
METHODS: Patients with SLE and population controls without history of clinical CV events who performed carotid ultrasound examination were recruited for this study. The outcome was incident CV event and death. Event-free survival rates were compared using Kaplan-Meier curves. Relative HR (95% CI) was used to estimate risk of outcome.
RESULTS: Patients (n=99, 87% female), aged 47 (13) years and with a disease duration of 12 (9) years, had mild disease at inclusion, Systemic Lupus Erythematosus Diseases Activity Index score of 3 (1-6) and Systemic Lupus International Collaborating Clinics (SLICC) Damage Index score of 0 (0-1). The controls (n=109, 91% female) were 49 (12) years old. Baseline carotid intima-media thickness (cIMT) did not differ between the groups, but plaques were more prevalent in patients (p=0.068). During 10.1 (9.8-10.2) years, 12 patients and 4 controls reached the outcome (p=0.022). Compared with the controls, the risk of the adverse outcome in patients increased threefold to fourfold taking into account age, gender, history of smoking and diabetes, family history of CV, baseline body mass index, waist circumference, C reactive protein, total cholesterol, high-density lipoprotein, low-density lipoprotein, dyslipidaemia, cIMT and presence of carotid plaque. In patients, higher SLICC score and SLE-antiphospholipid syndrome (SLE-APS) were associated with increased risk of the adverse outcome, with respective HRs of 1.66 (95% CI 1.20 to 2.28) and 9.08 (95% CI 2.71 to 30.5), as was cIMT with an HR of 1.006 (95% CI 1.002 to 1.01). The combination of SLICC and SLE-APS with cIMT significantly improved prediction of the adverse outcome (p<0.001).
CONCLUSION: In patients with mild SLE of more than 10 years duration, there is a threefold to fourfold increased risk of CV events and death compared with persons who do not have SLE with similar pattern of traditional CV risk factors, cIMT and presence of carotid plaque. SLICC, SLE-APS and subclinical atherosclerosis may indicate a group at risk of worse outcome in SLE. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  antiphospholipid syndrome; atherosclerosis; cardiovascular diseases; lupus erythematosus; systemic

Mesh:

Year:  2021        PMID: 33547230      PMCID: PMC7871345          DOI: 10.1136/lupus-2020-000454

Source DB:  PubMed          Journal:  Lupus Sci Med        ISSN: 2053-8790


  56 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study.

Authors:  Hung-Lin Chen; Li-Jiuan Shen; Ping-Ning Hsu; Chieh-Yu Shen; Susan A Hall; Fei-Yuan Hsiao
Journal:  J Rheumatol       Date:  2017-11-15       Impact factor: 4.666

3.  Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

Authors:  R Cervera; R Serrano; G J Pons-Estel; L Ceberio-Hualde; Y Shoenfeld; E de Ramón; V Buonaiuto; S Jacobsen; M M Zeher; T Tarr; A Tincani; M Taglietti; G Theodossiades; E Nomikou; M Galeazzi; F Bellisai; P L Meroni; R H W M Derksen; P G D de Groot; M Baleva; M Mosca; S Bombardieri; F Houssiau; J-C Gris; I Quéré; E Hachulla; C Vasconcelos; A Fernández-Nebro; M Haro; Z Amoura; M Miyara; M Tektonidou; G Espinosa; M L Bertolaccini; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2014-01-24       Impact factor: 19.103

4.  Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

Authors:  Guillermo J Pons-Estel; Luis A González; Jie Zhang; Paula I Burgos; John D Reveille; Luis M Vilá; Graciela S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2009-05-19       Impact factor: 7.580

Review 5.  Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review.

Authors:  Konstantinos Tselios; Barry J Sheane; Dafna D Gladman; Murray B Urowitz
Journal:  J Rheumatol       Date:  2015-11-15       Impact factor: 4.666

6.  Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus.

Authors:  Harmony R Reynolds; Jill Buyon; Mimi Kim; Tania L Rivera; Peter Izmirly; Paul Tunick; Robert M Clancy
Journal:  Atherosclerosis       Date:  2009-12-16       Impact factor: 5.162

7.  SLE mortality remains disproportionately high, despite improvements over the last decade.

Authors:  R R Singh; E Y Yen
Journal:  Lupus       Date:  2018-07-17       Impact factor: 2.911

8.  Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center.

Authors:  Rosa Serrano; Guillermo J Pons-Estel; Gerard Espinosa; Rosana M Quintana; Joan C Reverter; Dolors Tassies; Joan Monteagudo; Ricard Cervera
Journal:  Lupus       Date:  2020-06-14       Impact factor: 2.911

9.  Changing paradigms in the treatment of systemic lupus erythematosus.

Authors:  Antonis Fanouriakis; George Bertsias
Journal:  Lupus Sci Med       Date:  2019-02-08

10.  Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?

Authors:  Charis Pericleous; Amrita D'Souza; Thomas McDonnell; Vera M Ripoll; Oliver Leach; David Isenberg; Ian Giles; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2020-01-01       Impact factor: 7.580

View more
  7 in total

Review 1.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

Review 2.  Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus.

Authors:  Christopher B Oliveira; Mariana J Kaplan
Journal:  Semin Immunopathol       Date:  2022-03-30       Impact factor: 11.759

Review 3.  Novel Surrogate Markers of Cardiovascular Risk in the Setting of Autoimmune Rheumatic Diseases: Current Data and Implications for the Future.

Authors:  Anna Mandel; Andreas Schwarting; Lorenzo Cavagna; Konstantinos Triantafyllias
Journal:  Front Med (Lausanne)       Date:  2022-06-30

4.  Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.

Authors:  Rahul M Kakalij; Del L Dsouza; Erika I Boesen
Journal:  Front Physiol       Date:  2022-07-06       Impact factor: 4.755

Review 5.  The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.

Authors:  Madhu Ramaswamy; Raj Tummala; Katie Streicher; Andre Nogueira da Costa; Philip Z Brohawn
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

6.  Study of common hypertriglyceridaemia genetic variants and subclinical atherosclerosis in a group of women with SLE and a control group.

Authors:  Marta Fanlo-Maresma; Virginia Esteve-Luque; Xavier Pintó; Ariadna Padró-Miquel; Emili Corbella; Beatriz Candás-Estébanez
Journal:  Lupus Sci Med       Date:  2022-08

7.  Hypercholesterolemia promotes autoantibody production and a lupus-like pathology via decreased DNase-mediated clearance of DNA.

Authors:  Umesh Kumar Dhawan; Andreas Margraf; Maciej Lech; Manikandan Subramanian
Journal:  J Cell Mol Med       Date:  2022-09-13       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.